Learn how and why Atom Bioscience is developing a new treatments for gout — and the impact it may have on millions of lives.

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout, acute gout and others for which there are no effective treatments.

Atom’s lead product, ABP-671, is in multicenter Phase 2b/3 clinical trials worldwide, including the US, for treatment of chronic gout. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs.

Another small molecule, ABP-745, has shown significant efficacy and good safety in animal models of anti-inflammation. ABP-745 has also demonstrated safety and efficacy in pre-clinical trials for acute gout and other anti-inflammation diseases and is in Phase 1 clinical trials.

Latest News from Atom Bioscience

12 January, 2024
Pipeline Review: Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout
02 January, 2024
Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout
16 October, 2023
Endpoints: Atom Bioscience raises $83M in Series D for URAT1 inhibitor in chronic gout treatment
16 October, 2023
Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout
More Atom News